IOVANCE BIOTHERAPEUTICS, INC. — Director's Dealing 2013

May 30, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Genesis Biopharma, Inc (GNBP)
CIK: 0001425205
Period of Report: 2013-05-22

Reporting Person: VOYTICKY DAVID J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-05-22	Common Stock	J	5627867	$0.01	Acquired	5627867	Direct
2013-05-22	12% Convertible Note due 2012	J	50000	$0.01	Disposed		Direct

Footnotes

F1: Outstanding debt of the reporting person, including interest and penalties thereon in an aggregate amount of $56,627.67, was converted into shares of Common Stock of the issuer pursuant to the terms of the Restructuring and Exchange Agreement, as further described on Current Report on Form 8-K filed with the SEC on May 29, 2013.

F2: Per share. Consideration for such shares paid by conversion of outstanding debt, including interest and penalties thereon, in an aggregate amount of $56,278.67.

F3: At the reporting person's sole discretion, the outstanding balance of the note may be converted into, or exchanged for, securities issued in the issuer's next capital raise on the same terms and conditions as are offered to any future investors, including to be determined, the rate of exchange.